Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck vaqta (hepatitis A vaccine, legacy) — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, Q4 2023
29
Period ended Dec 31, 2023
Change on a year earlier
-25.6%
39 in Q4 2022
History
24 quarters
Since Q1 2018
Sources
19
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up vaqta (hepatitis a vaccine, legacy) — worldwide sales ($m)
Cite this data
StockData. (2026). Merck Vaqta (hepatitis A vaccine, legacy) — Worldwide sales ($M) ($M), quarterly Q1 2018–Q4 2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_vaqta
See every metric in the Merck KPI table. Data updated Oct 26, 2026.